It is of note, however, that in the paediatric trial NCT03194932, all three AML patients with somatic NF1 mutations demonstrated BCL2 dependence in BH3-dependence testing and two of them demonstrated CR with a FC-MRD < 0.1% post first cycle, while the third PR had an FC-MRD between 0.1 and 5% [13]. This evidence concerns the gene NF1 and acute myeloid leukemia.